2000至2023年美国毒物中心报告的米多君暴露趋势与结局
该研究对2000年1月1日至2023年12月31日美国国家毒物数据系统®中单物质米多君暴露进行回顾性分析,共1935例,并用IQVIA数据描述零售配药趋势。零售米多君配药人数从2002年55300增至2023年439659(增加695%),暴露呼叫从2000年21例增至2023年171例(增加714%)。最常见临床表现为高血压277例(14.3%)和心动过缓197例(10.2%);除13-19岁青少年外多数年龄组以治疗错误为主,青少年组疑似自杀占50.2%。多数暴露在家中处理;866例就诊者中437例(50.5%)经治疗/评估后离院,115例(13.3%)收入重症监护室。作者认为更好理解米多君暴露及结局可指导毒物中心分诊与医疗管理,改进监测与临床医生认知可能降低米多君毒性相关并发症与死亡。
要点
- 2000至2023年共报告1935例单物质米多君暴露,呼叫数从2000年21例增至2023年171例,增加714%。
- 零售米多君配药人数从2002年55300增至2023年439659,增加695%,与暴露增加同时出现。
- 最常见表现为高血压277例(14.3%)和心动过缓197例(10.2%)。
- 13-19岁青少年中最常见暴露原因为疑似自杀(50.2%),其余多数年龄组以治疗错误为主。
- 866例就诊者中115例(13.3%)收入重症监护室,437例(50.5%)经治疗/评估后离院;多数暴露在家中处理。
适用人群与场景
- 2000年1月1日至2023年12月31日向美国国家毒物数据系统®报告的单物质米多君暴露患者,覆盖各年龄组。
- 暴露增加主要集中在20-59岁和60岁及以上人群。
红旗征与不能漏的情况
- 高血压(277例,14.3%)和心动过缓(197例,10.2%)是米多君暴露最常见的临床特征。
- 13-19岁青少年中疑似自杀占暴露原因的50.2%,该人群较治疗错误者报告了更严重的不良反应。
研究设计与关键结果
- 回顾性分析美国国家毒物数据系统®中2000年1月1日至2023年12月31日单物质米多君暴露共1935例,零售配药数据来自IQVIA Total Patient Tracker(2002-2023年)。
- 零售药房米多君配药人数从2002年55300增至2023年439659,增加695%;毒物中心暴露呼叫从2000年21例增至2023年171例,增加714%。
- 最常见特征为高血压277例(14.3%)和心动过缓197例(10.2%)。
- 除13-19岁青少年外,多数年龄组以治疗错误为主;13-19岁组疑似自杀占50.2%。
- 多数暴露在家中处理;866例寻求医疗照顾的患者中,437例(50.5%)经治疗/评估后离院,115例(13.3%)收入重症监护室。
证据类型、等级与局限
- 证据类型:基于美国国家毒物数据系统®的回顾性分析。
- 局限:美国国家毒物数据系统®受被动监测设计限制,并非所有暴露均被报告。
对床旁实践的改变
- 作者认为,更好理解米多君暴露及相关结局可为毒物中心分诊和医疗管理提供信息。
- 作者认为,改进监测和临床医生认知可能降低米多君毒性相关的并发症和死亡。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: Midodrine is an oral alpha-1 adrenergic agonist used to treat orthostatic hypotension. Its vasoconstrictive properties can lead to hypertension and reflex bradycardia. We characterized midodrine exposures reported to United States poison centers from 2000 to 2023.
METHODS: We performed a retrospective analysis of single-substance midodrine exposures reported to the National Poison Data System®. Descriptive statistics were used to characterize temporal trends, demographics, exposure reasons, level of healthcare, and medical outcomes. National estimates of retail outpatient midodrine prescriptions during 2002-2023 were obtained from IQVIA Total Patient Tracker.
RESULTS: The number of patients dispensed midodrine from retail pharmacies increased 695%, from 55,300 in 2002 to 439,659 in 2023. There were 1,935 midodrine exposures reported to the National Poison Data System® from 1 January 2000 to 31 December 2023. Exposures increased 714%, from 21 calls in 2000 to 171 calls in 2023. The most common features reported were hypertension in 277 (14.3%) and bradycardia in 197 (10.2%). Therapeutic errors accounted for most cases in most age groups except adolescents aged 13-19 years, in which suspected suicide was the most commonly reported reason (50.2%). Most exposures were managed at home. Among 866 patients who sought medical care, 437 (50.5%) were treated/evaluated and released, but 115 (13.3%) were admitted to a critical care unit.
DISCUSSION: Midodrine exposures increased over time, particularly among individuals aged 20-59 years and 60 years and older, with a concomitant increase in retail midodrine dispensing. Although most exposures were managed at home, severe adverse effects have been reported, especially among patients with suspected suicidal ingestions compared to those with therapeutic errors. The National Poison Data System® is limited by its passive surveillance design, and not all exposures are reported.
CONCLUSIONS: Better understanding of midodrine exposures and associated outcomes can inform poison center triage and medical management. Improved surveillance and clinician awareness may reduce morbidity and mortality associated with midodrine toxicity.
参考来源
- Kuai D, Nogee DP, Kieszak S, et al. Midodrine exposure trends and outcomes reported to United States poison centers: 2000-2023. Clin Toxicol (Phila). 2025. PMID: 40874904. doi:10.1080/15563650.2025.2546073
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。